Article

Timing of convalescent plasma administration and 28-day mortality for COVID-19 pneumonia

2021-02-03

Abstract excerpt

<h4>Summary</h4> Convalescent plasma administration (CPA) is widely used to treat Covid-19, but its effectiveness remains controversial. Here we report the results of an Expanded Access Program of CPA in the province of Buenos Aires, Argentina. We evaluated the relationship between the timing of CPA and 28-day mortality in 4719 hospitalized patients with COVID-19 pneumonia. Early (≤3 days from admission) CPA was a...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 8ef1f7b4-6406-5447-a59f-1f16bd32c7ca
DOI: 10.1101/2021.02.02.21250758

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Timing of convalescent plasma administration and 28-day mortality for COVID-19 pneumoniaDOI 10.1101/2021.02.02.21250758Read

COVID-19 convalescent plasma to treat hospitalised COVID-19 patients with or without underlying immunodeficiency: a randomized trialSemantic proximity Read

Efficacy and safety of convalescent plasma therapy for severe COVID-19 patients：case series study and literature reviewSemantic proximity Read

Convalescent Plasma Therapy for COVID-19: A Graphical Mosaic of the Worldwide EvidenceSemantic proximity Read

On whether therapeutic plasma exchange is an effective cure against severe/critical COVID-19 pneumoniaSemantic proximity Read

On Whether Therapeutic Plasma Exchange is Effective Against Severe/Critical COVID-19 PneumoniaSemantic proximity Read

Randomised Clinical Trial to Evaluate Safety and Efficacy of Convalescent Plasma Use Among Hospitalized Patients with COVID-19 (PERUCONPLASMA): A Structured Summary af a Study Protocol for a Randomised Controlled Trial.Semantic proximity Read

A randomized, double-blind, controlled trial of convalescent plasma in adults with severe COVID-19Semantic proximity Read

Association of Convalescent Plasma Treatment with Reduced Mortality and Improved Clinical Trajectory in Patients Hospitalized with COVID-19 in the Community SettingSemantic proximity Read

Randomized Controlled Trial of Early Outpatient COVID-19 Treatment with High-Titer Convalescent PlasmaSemantic proximity Read

Prognostic factors for COVID-19 pneumonia progression to severe symptom based on the earlier clinical features: a retrospective analysisSemantic proximity Read

COVID-19 convalescent plasma and randomized clinical trials: explaining conflicting outcomes and finding signals of efficacySemantic proximity Read

Azvudine Reduce the In-Hospital Mortality of Patients with COVID-19 PneumoniaSemantic proximity Read